Post by Light Chain Bioscience | Novimmune SA

Light Chain Bioscience | Novimmune SA is pleased to announce that positive data - including overall survival - in heavily pretreated platinum resistant ovarian cancer (PROC) patients were presented today at #ESMO25. The study involved the combination of innate and adaptive immune checkpoint blockade in a chemotherapy-free regimen, in a patient population for whom there is currently no standard of care. We believe these results are noteworthy in an indication that has largely proven resistant to immunotherapy. link to press release https://lnkd.in/eCHZ5_Wb light chain bioscience https://lnkd.in/e2GRfqGa #ovariancancer #ESMO25 #CD47